Achilles Therapeutics PLC ADR ACHL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACHL is a good fit for your portfolio.
News
-
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
-
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
-
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
Trading Information
- Previous Close Price
- $0.79
- Day Range
- $0.77–0.83
- 52-Week Range
- $0.74–1.76
- Bid/Ask
- $0.76 / $0.87
- Market Cap
- $32.41 Mil
- Volume/Avg
- 111,844 / 796,582
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 215
- Website
- https://www.achillestx.com
Valuation
|
Metric
|
ACHL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.23 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ACHL
|
|---|---|
Quick Ratio | 8.35 |
Current Ratio | 8.57 |
Interest Coverage | — |
Quick Ratio
ACHL
Profitability
|
Metric
|
ACHL
|
|---|---|
Return on Assets (Normalized) | −33.50% |
Return on Equity (Normalized) | −37.89% |
Return on Invested Capital (Normalized) | −36.29% |
Return on Assets
ACHL
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fsvjqfhj | Xpzq | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pnsshdp | Krmgv | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hcysprgt | Bybvfw | $98.8 Bil | |
MRNA
| Moderna Inc | Jxpfnwmn | Ydckh | $38.8 Bil | |
ARGX
| argenx SE ADR | Xfcyfsvpd | Xmlh | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Nqwxfyr | Jsmc | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mbbwhllm | Lvtryq | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Sjmpbhjl | Khvpmr | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Drzvqsdp | Qsgbrc | $12.4 Bil | |
INCY
| Incyte Corp | Wsjmcnpg | Nshvgb | $11.9 Bil |